Systemic review and meta-analysis to assess the efficacy of allogenic hematopoietic cell transplantation in Mantle cell lymphoma when using myeloablative conditioning or reduced-intensity conditioning regimes.
Niraparib, a highly selective PARP inhibitor, has been demonstrated to significantly improve progression-free survival in patients with platinum-sensitive recurrent ovarian cancer, regardless of BRCA-mutation status.
The results of a Phase III randomized trial presented at ASCO 2015 have indicated that the use of nivolumab alone or in combination with ipilimumab for the treatment of melanoma is more effective than the use of ipilimumab alone.
The latest results from a Phase II prospective, multicenter study published recently in The New England Journal of Medicine indicate that ibrutinib may be successful in controlling Waldenström’s macroglobulinemia.
A Phase II clinical trial has found that sunitinib shows significant cancer-fighting activity in patients with advanced differentiated thyroid cancer.
Survival more than doubled for certain stage IV lung cancer patients in a clinical trial that combined stereotactic body radiation therapy (SBRT) with an erlotinib chemotherapy regimen.
Rutgers Cancer Institute of New Jersey (NJ, USA) investigators recently presented data from a Phase II clinical trial demonstrating that a combination of doxil, carboplatin and bevacizumab is a well-tolerated treatment regimen for metastatic triple-negative breast cancer.
This review provides an overview of the basic mechanisms of angiogenesis and presents evidence of the efficacy/potential benefits of antiangiogenic therapy.
Researchers at the Dana-Farber Cancer Institute presented their study’s findings at the 56th American Society of Hematology annual meeting, suggesting signals sent by multiple myeloma cells could provide an insight into the efficacy of treatments for individual patients.
New data released recently by Genmab A/S (Denmark) has indicated that ofatumumab maintenance therapy could have an impact on the progression-free survival (PFS) of patients with relapsed chronic lymphocytic leukemia (CLL).
